Molecular epidemiologic and clinical analysis of Helicobacter cinaedi bacteremia in Japan.
Journal
Helicobacter
ISSN: 1523-5378
Titre abrégé: Helicobacter
Pays: England
ID NLM: 9605411
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
02
09
2019
revised:
22
10
2019
accepted:
23
10
2019
pubmed:
23
11
2019
medline:
30
5
2020
entrez:
23
11
2019
Statut:
ppublish
Résumé
Helicobacter cinaedi is an important pathogen that causes bloodstream infections. Owing to the challenges in its culture and identification, its clinical and bacterial characteristics remain unknown. Our study aimed to investigate the molecular epidemiology and antimicrobial susceptibility of H cinaedi. From 2003 to 2016, we analyzed 16 non-repetitive H cinaedi strains, isolated from blood, at the medical hospital of Tokyo Medical and Dental University. Multilocus sequence typing was performed to analyze the genetic relationship across the different isolates. The minimum inhibitory concentrations (MIC) of antibiotics were determined by the agar dilution method. The median age of subjects in this study was 61 years (range, 18-84 years). The most common risk factors included the use of steroids (75.0%) and immunosuppressant drugs (37.5%). In addition, the most common symptoms of H cinaedi bacteremia included colitis (37.5%) and cellulitis (31.3%). The infection recurred in three of seven cases (42.8%) that underwent antibiotic therapy for <10 days. The strains were classified into five sequence types (ST), of which, ST 10 (43.8%) and ST 4 (31.3%) were predominant. The MIC Since there is no recommended guideline yet for the choice or duration of antibiotic therapy and antimicrobial break points, our results suggested, for the first time, that prolonged antibiotic therapy, except with ciprofloxacin and clarithromycin, would be required to ensure resolution of symptoms and prevention of recurrence.
Sections du résumé
BACKGROUND
BACKGROUND
Helicobacter cinaedi is an important pathogen that causes bloodstream infections. Owing to the challenges in its culture and identification, its clinical and bacterial characteristics remain unknown. Our study aimed to investigate the molecular epidemiology and antimicrobial susceptibility of H cinaedi.
MATERIALS AND METHODS
METHODS
From 2003 to 2016, we analyzed 16 non-repetitive H cinaedi strains, isolated from blood, at the medical hospital of Tokyo Medical and Dental University. Multilocus sequence typing was performed to analyze the genetic relationship across the different isolates. The minimum inhibitory concentrations (MIC) of antibiotics were determined by the agar dilution method.
RESULTS
RESULTS
The median age of subjects in this study was 61 years (range, 18-84 years). The most common risk factors included the use of steroids (75.0%) and immunosuppressant drugs (37.5%). In addition, the most common symptoms of H cinaedi bacteremia included colitis (37.5%) and cellulitis (31.3%). The infection recurred in three of seven cases (42.8%) that underwent antibiotic therapy for <10 days. The strains were classified into five sequence types (ST), of which, ST 10 (43.8%) and ST 4 (31.3%) were predominant. The MIC
CONCLUSIONS
CONCLUSIONS
Since there is no recommended guideline yet for the choice or duration of antibiotic therapy and antimicrobial break points, our results suggested, for the first time, that prolonged antibiotic therapy, except with ciprofloxacin and clarithromycin, would be required to ensure resolution of symptoms and prevention of recurrence.
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12675Subventions
Organisme : JSPS KAKENHI
ID : 19K10554
Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Totten PA, Fennell CL, Tenover FC, et al. Campylobacter cinaedi (sp. nov.) and Campylobacter fennelliae (sp. nov.): two new Campylobacter species associated with enteric disease in homosexual men. J Infect Dis. 1985;151:131-139.
Kiehlbauch JA, Tauxe RV, Baker CN, Wachsmuth IK. Helicobacter cinaedi-associated bacteremia and cellulitis in immunocompromised patients. Ann Intern Med. 1994;121:90-93.
Imafuku A, Araoka H, Tanaka K, et al. Helicobacter cinaedi bacteremia in four renal transplant patients: clinical features and an important suggestion regarding the route of infection. Transpl Infect Dis. 2016;18:132-136.
Burman WJ, Cohn DL, Reves RR, Wilson ML. Multifocal cellulitis and monoarticular arthritis as manifestations of Helicobacter cinaedi bacteremia. Clin Infect Dis. 1995;20:564-570.
Bartels H, Goldenberger D, Reuthebuch O, et al. First case of infective endocarditis caused by Helicobacter cinaedi. BMC Infect Dis. 2014;14:586.
Okubo H, Goto M, Sato M, et al. Helicobacter cinaedi meningitis: a case report and review of previous cases. J Neurol Sci. 2014;347:396-397.
Matsumoto T, Goto M, Murakami H, et al. Multicenter study to evaluate bloodstream infection by Helicobacter cinaedi in Japan. J Clin Microbiol. 2007;45:2853-2857.
Araoka H, Baba M, Kimura M, Abe M, Inagawa H, Yoneyama A. Clinical characteristics of bacteremia caused by Helicobacter cinaedi and time required for blood cultures to become positive. J Clin Microbiol. 2014;52:1519-1522.
Kitamura T, Kawamura Y, Ohkusu K, et al. Helicobacter cinaedi cellulitis and bacteremia in immunocompetent hosts after orthopedic surgery. J Clin Microbiol. 2007;45:31-38.
Uwamino Y, Muranaka K, Hase R, Otsuka Y, Hosokawa N. Clinical features of community-acquired Helicobacter cinaedi bacteremia. Helicobacter. 2016;21:24-28.
Hiyama Y, Takahashi S, Nishiyama N, et al. Four cases of bacteremia caused by Helicobacter cinaedi in the urological ward at about the same time. Hinyokika Kiyo. 2017;63:461-463.
Gotoh Y, Taniguchi T, Yoshimura D, et al. Multi-step genomic dissection of a suspected intra-hospital Helicobacter cinaedi outbreak. Microb Genom. 2019;5:1-7.
Minauchi K, Takahashi S, Sakai T, et al. The nosocomial transmission of Helicobacter cinaedi infections in immunocompromised patients. Intern Med. 2010;49:1733-1739.
Rimbara E, Mori S, Kim H, et al. Helicobacter cinaedi and Helicobacter fennelliae transmission in a hospital from 2008 to 2012. J Clin Microbiol. 2013;51:2439-2442.
Rimbara E, Mori S, Matsui M, et al. Molecular epidemiologic analysis and antimicrobial resistance of Helicobacter cinaedi isolated from seven hospitals in Japan. J Clin Microbiol. 2012;50:2553-2560.
Kakuta R, Yano H, Kanamori H, et al. Helicobacter cinaedi infection of abdominal aortic aneurysm, Japan. Emerg Infect Dis. 2014;20:1942-1945.
Friedman ND, Kaye KS, Stout JE, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002;137:791-797.
Tomida J, Oumi A, Okamoto T, et al. Comparative evaluation of agar dilution and broth microdilution methods for antibiotic susceptibility testing of Helicobacter cinaedi. Microbiol Immunol. 2013;57:353-358.
Taylor NS, Ge Z, Shen Z, Dewhirst FE, Fox JG. Cytolethal distending toxin: a potential virulence factor for Helicobacter cinaedi. J Infect Dis. 2003;188:1892-1897.
Kawakami Y. Clinical and bacteriological examination in hospital of Helicobacter cinaedi (H. cinaedi). Kansenshogaku Zasshi. 2014;88:417-422.
Khan S, Rahman HN, Okamoto T, et al. Promotion of atherosclerosis by Helicobacter cinaedi infection that involves macrophage-driven proinflammatory responses. Sci Rep. 2014;4:4680.
Araoka H, Baba M, Okada C, et al. Risk factors for recurrent Helicobacter cinaedi bacteremia and the efficacy of selective digestive decontamination with kanamycin to prevent recurrence. Clin Infect Dis. 2018;67:573-578.
Kuijper EJ, Stevens S, Imamura T, De Wever B, Claas EC. Genotypic identification of erythromycin-resistant campylobacter isolates as helicobacter species and analysis of resistance mechanism. J Clin Microbiol. 2003;41:3732-4373.
Abiko S, Nakamura I, Yamaguchi Y, Ohkusu K, Hirayama Y, Matsumoto T. The first case report of cerebral cyst infection due to Helicobacter cinaedi. Jpn J Infect Dis. 2017;70:210-212.